Americas Pharma Intelligence Center

Revuforj (revumenib) is FDA-approved for relapsed or refractory acute leukemia with KMT2A translocation and for relapsed or refractory AML with susceptible NPM1 mutation, both in adult and pediatric patients 1 year and older.

The Phase 3 PURPOSE 1 trial demonstrated 100% efficacy for twice-yearly injectable lenacapavir in preventing HIV-1 infection in cisgender women.

On January 26, 2023, the FDA approved pembrolizumab (Keytruda) for adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC.

Revuforj (revumenib) is FDA-approved for relapsed or refractory acute leukemia with KMT2A translocation and for relapsed or refractory AML with susceptible NPM1 mutation, both in adult and pediatric patients 1 year and older.

REZPEG is in active Phase 2 development for atopic dermatitis and alopecia areata, with a completed Phase 2 lupus trial providing clinical breadth.

Dupixent was Sanofi's best-selling pharmaceutical product in 2025 , cementing its role as the company's commercial anchor.

Tillomed Laboratories is owned by Emcure , a privately held pharmaceutical company positioned as a diversified generics and specialty-pharma business.

Eli Lilly’s pipeline story is no longer limited to diabetes and obesity; the company has committed roughly $4 billion to a trio of vaccine-related deals.

Sanofi acquired all outstanding Inhibrx shares for $30.00 per share in cash , representing an equity value of approximately $1.7 billion on a fully diluted basis.